VANCOUVER, British Columbia, Nov. 14, 2017 (GLOBE NEWSWIRE) — Harvest One Cannabis Inc. (TSXV:HVST) (“Harvest One” or the “Company“) through its wholly owned Swiss subsidiary, Satipharm AG (“Satipharm“), is pleased to advise that it’s Melbourne-based distribution partner, HL Pharma Pty Ltd (“HL Pharma”), has commenced distribution of Satipharm’s Gelpell-CBD™ capsules to approved patients in Australia.
- Melbourne-based distribution partner HL Pharma commences distribution of Satipharm’s Gelpell-CBD™ capsules to approved patients in Australia
- Gelpell-CBD™ capsules are one of the first medicinal cannabis products available to approved patients in Australia
- Delivery of first products to Australian patients solidifies Australian market position and provides foundation for near-term revenue growth
The commencement of Satipharm sales in Australia is part of a comprehensive strategy to expand the international distribution of its products for commercial and clinical research purposes. Satipharm is focused on developing cutting-edge dose delivery technology for pharmaceutical-grade cannabis products providing physicians